Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Society for Biomaterials is hosting its Annual Meeting and Exposition (US) April 2002:

This article was originally published in Clinica

Executive Summary

The Society for Biomaterials is hosting its 28th Annual Meeting and Exposition on April 25-27 2002 at the Tampa Convention Center, Tampa, Florida. The event, which includes technical and poster sessions, workshops and tutorials, focuses on the latest developments in biomaterials research. Key areas include ophthalmic biomaterials, nano-materials, materials for nerve regeneration, biomaterials for cardiac assist devices, stem cell-based therapies, biomaterials for gene therapy and dental and orthopaedic materials. Further details from the Society for Biomaterials in Minneapolis on tel: +1 763 543 0908; fax: +1 763 765 2329; email: registration@biomateriasl.org www.biomaterials.org

You may also be interested in...



EU Turns Up Heat On PFAS With Broad REACH Restriction Proposal In The Works

Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.

Keeping Track: Tauvid, Oriahnn, Artesunate Clear US FDA, Along With Trio Of Pediatric Approvals

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

Topics

UsernamePublicRestriction

Register

WI964848

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel